Literature DB >> 17705002

Comparison of urethral diameters for calculating the urethral dose after permanent prostate brachytherapy.

Osamu Tanaka1, Shinya Hayashi, Masayuki Matsuo, Masahiro Nakano, Yasuaki Kubota, Sunaho Maeda, Kazuhiro Ohtakara, Takashi Deguchi, Hiroaki Hoshi.   

Abstract

PURPOSE: No studies have yet evaluated the effects of a dosimetric analysis for different urethral volumes. We therefore evaluated the effects of a dosimetric analysis to determine the different urethral volumes.
METHODS: This study was based on computed tomography/magnetic resonance imaging (CT/MRI) combined findings in 30 patients who had undergone prostate brachytherapy. Postimplant CT/MRI scans were performed 30 days after the implant. The urethra was contoured based on its diameter (8, 6, 4, 2, and 0 mm). The total urethral volume-in cubic centimeters [UrV150/200(cc)] and percent (UrV150%/200%), of the urethra receiving 150% or 200% of the prescribed dose-and the doses (UrD90/30/5) in Grays to 90%, 30%, and 5% of the urethral volume were measured based on the urethral diameters.
RESULTS: The UrV150(cc) and UrD30 were statistically different between the of 8-, 6-, 4-, 2-, and 0-mm diameters, whereas the UrD5 was statistically different only between the 8-, 6-, and 4-mm diameters. Especially for UrD5, there was an approximately 40-Gy difference between the mean values for the 8- and 0-mm diameters.
CONCLUSION: We recommend that the urethra should be contoured as a 4- to 6-mm diameter circle or one side of a triangle of 5-7 mm. By standardizing the urethral diameter, the urethral dose will be less affected by the total urethral volume.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17705002     DOI: 10.1007/s11604-007-0146-2

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  19 in total

1.  Determination of the urethral dose in prostate brachytherapy when the urethra cannot be visualized in the postimplant CT scan.

Authors:  F M Waterman; A P Dicker
Journal:  Med Phys       Date:  2000-03       Impact factor: 4.071

Review 2.  The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis.

Authors:  S Nag; W Bice; K DeWyngaert; B Prestidge; R Stock; Y Yu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-01       Impact factor: 7.038

3.  Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy.

Authors:  Mohamed A Elshaikh; Kenneth Angermeier; James C Ulchaker; Eric A Klein; Mark A Chidel; Stephen Mahoney; D Allan Wilkinson; Chandana A Reddy; Jay P Ciezki
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

4.  Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer.

Authors:  Hoon K Lee; Warren D D'Souza; Jose-Miguel J Yamal; Alan Pollack; Andrew K Lee; Matthew B Palmer; Deborah A Kuban
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-10-01       Impact factor: 7.038

5.  Risk factors for the development of prostate brachytherapy related urethral strictures.

Authors:  Gregory S Merrick; Wayne M Butler; Kent E Wallner; Robert W Galbreath; Richard L Anderson; Zachariah A Allen; Edward Adamovich
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

6.  Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.

Authors:  D Y Gelblum; L Potters; R Ashley; R Waldbaum; X H Wang; S Leibel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-08-01       Impact factor: 7.038

7.  The dosimetry of prostate brachytherapy-induced urethral strictures.

Authors:  Gregory S Merrick; Wayne M Butler; Bryan G Tollenaar; Robert W Galbreath; Jonathan H Lief
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

8.  Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.

Authors:  Zachariah A Allen; Gregory S Merrick; Wayne M Butler; Kent E Wallner; Brian Kurko; Richard L Anderson; Brian C Murray; Robert W Galbreath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

Review 9.  American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy.

Authors:  Subir Nag; Rodney J Ellis; Gregory S Merrick; Robert Bahnson; Kent Wallner; Richard Stock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

10.  Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy.

Authors:  K Wallner; J Roy; L Harrison
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-05-15       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.